Erbitux
(Cetuximab)
(500 mg)
(one)
(Фл)
Erbitux (cetuximab) 500 mg, Merck, Germany
Article:
In Stock
Colorectal Cancer (CRC)
Erbitux is indicated for patients with epidermal growth factor receptor (EGFR)-expressing, RAS wild-type (without mutation) metastatic colorectal cancer, strictly as determined by approved testing.
-
Commercial name:Erbitux
-
Сhemical name:Cetuximab
-
Dosage:500 mg
-
Quantity:one
-
Release form:Фл
No reviews yet